Your browser doesn't support javascript.
loading
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
Msaouel, Pavlos; Goswami, Sangeeta; Thall, Peter F; Wang, Xuemei; Yuan, Ying; Jonasch, Eric; Gao, Jianjun; Campbell, Matthew T; Shah, Amishi Yogesh; Corn, Paul Gettys; Tam, Alda L; Ahrar, Kamran; Rao, Priya; Sircar, Kanishka; Cohen, Lorenzo; Basu, Sreyashi; Duan, Fei; Jindal, Sonali; Zhang, Yuwei; Chen, Hong; Yadav, Shalini S; Shazer, Ronald; Der-Torossian, Hirak; Allison, James P; Sharma, Padmanee; Tannir, Nizar M.
Afiliação
  • Msaouel P; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Goswami S; David H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Thall PF; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Wang X; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Yuan Y; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Jonasch E; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Gao J; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Campbell MT; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Shah AY; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Corn PG; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Tam AL; David H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Ahrar K; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Rao P; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Sircar K; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Cohen L; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Basu S; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Duan F; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Jindal S; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Zhang Y; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Chen H; Department of Palliative, Rehabilitation and Integrative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Yadav SS; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Shazer R; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Der-Torossian H; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Allison JP; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Sharma P; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Tannir NM; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sci Transl Med ; 14(641): eabm6420, 2022 04 20.
Article em En | MEDLINE | ID: mdl-35442707
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos